Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1994 3
2002 2
2004 1
2005 1
2007 2
2012 1
2013 3
2014 2
2016 1
2017 2
2018 3
2019 6
2020 9
2021 12
2022 7
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.
Bourlon C, Roddie C, Menne T, Norman J, O'Reilly M, Gibb A, Besley C, Chaganti S, Arias CG, Jones C, Dikair A, Allen S, Seymour F, Osborne W, Mathew A, Townsend W, Patten PE, Thoulouli E, Abdulgawad A, Lugthart S, Sanderson R, Kirkwood AA, Kuhnl A. Bourlon C, et al. Among authors: townsend w. Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285010. Online ahead of print. Haematologica. 2024. PMID: 38572567 Free article.
Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia.
de Tute R, Counsell N, Clifton-Hadley L, D'Sa S, Pratt G, Campbell G, Campbell L, Sadler R, Townsend W, Popova B, Smith P, Schofield O, Owen R, Auer R. de Tute R, et al. Among authors: townsend w. Leukemia. 2024 Apr;38(4):822-828. doi: 10.1038/s41375-024-02162-5. Epub 2024 Feb 26. Leukemia. 2024. PMID: 38409530 Clinical Trial.
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.
Shotton R, Broadbent R, Alchawaf A, Mohamed MB, Gibb A, Martinez-Calle N, Fox CP, Bishton M, Pender A, Gleeson M, Cunningham D, Davies A, Yadollahi S, Eyre TA, Collins G, Djebbari F, Kassam S, Garland P, Watts E, Osborne W, Townsend W, Pocock R, Ahearne MJ, Miall F, Wang X, Linton KM. Shotton R, et al. Among authors: townsend w. Blood Adv. 2024 Feb 27;8(4):878-888. doi: 10.1182/bloodadvances.2023011305. Blood Adv. 2024. PMID: 37967358 Free PMC article.
Improved COVID-19 outcomes in CAR-T patients in the age of vaccination and preemptive pharmacotherapeutics.
Cheok KPL, Kirkwood AA, Creasey T, Tholouli E, Chaganti S, Mathew A, Dulobdas V, Irvine D, Besley C, Neil L, Lown R, Menne T, Townsend W, Kuhnl A, O'Reilly M, Sanderson R, Sanchez E, Roddie C. Cheok KPL, et al. Among authors: townsend w. Leuk Lymphoma. 2023 Dec;64(12):2037-2041. doi: 10.1080/10428194.2023.2248329. Epub 2023 Aug 21. Leuk Lymphoma. 2023. PMID: 37602678 No abstract available.
Tackling antimicrobial resistance: developing and implementing antimicrobial stewardship interventions in four African commonwealth countries through a health partnership model.
Ashiru-Oredope D, Nabiryo M, Zengeni L, Kamere N, Makotose A, Olaoye O, Townsend W, Waddingham B, Matuluko A, Nambatya W, Esseku Y, Bartimeus A, Mahjoub S, D'Arcy N, Tuck C, Cavanagh S, Geoola J, Muro EP, Munkombwe D, Fraser J, Skone-James R, Rutter V. Ashiru-Oredope D, et al. Among authors: townsend w. J Public Health Afr. 2023 Apr 21;14(6):2335. doi: 10.4081/jphia.2023.2335. eCollection 2023 Jun 21. J Public Health Afr. 2023. PMID: 37538939 Free PMC article.
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study.
Townsend W, Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer MJS, Gribben JG, Phillips EH, Dreyling M, Seymour JF, Grigg A, Trotman J, Lin TY, Hong XN, Kingbiel D, Nielsen TG, Knapp A, Herold M, Marcus R. Townsend W, et al. Hemasphere. 2023 Jun 30;7(7):e919. doi: 10.1097/HS9.0000000000000919. eCollection 2023 Jul. Hemasphere. 2023. PMID: 37404773 Free PMC article.
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.
Jurczak W, Elmusharaf N, Fox CP, Townsend W, Paulovich AG, Whiteaker JR, Krantz F, Wun CC, Parr G, Sharma S, Munugalavadla V, Manwani R, Dean E, Munir T. Jurczak W, et al. Among authors: townsend w. Ther Adv Hematol. 2023 May 30;14:20406207231173489. doi: 10.1177/20406207231173489. eCollection 2023. Ther Adv Hematol. 2023. PMID: 37273420 Free PMC article.
62 results